Angela M. Cacace - Jun 17, 2024 Form 4 Insider Report for ARVINAS, INC. (ARVN)

Role
Chief Scientific Officer
Signature
/s/ Jared Freedberg, as attorney-in-fact for Angela M. Cacace
Stock symbol
ARVN
Transactions as of
Jun 17, 2024
Transactions value $
$0
Form type
4
Date filed
6/18/2024, 05:53 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARVN Common Stock Award $0 +16K +44.61% $0.00 51.9K Jun 17, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARVN Stock Option (right to buy) Award $0 +24.6K $0.00 24.6K Jun 17, 2024 Common Stock 24.6K $24.94 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units (each, an "RSU") were granted by the issuer on June 17, 2024, pursuant to its 2018 Stock Incentive Plan (the "Plan") and each RSU represents a contingent right to receive one share of the issuer's common stock upon settlement for no consideration. The RSUs will vest over two years: 1/2 of the shares underlying the award shall vest on June 17, 2025, with the remainder of the shares vesting on June 17, 2026.
F2 The option was granted by the Issuer on June 17, 2024, pursuant to the Plan. The shares underlying the option will vest over two years: 1/2 of the shares underlying the award shall vest on June 17, 2025, with the remainder of the shares vesting on June 17, 2026.